Nuvectis Pharma Inc NVCT
News
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights